期刊文献+

隐匿性甲状腺癌淋巴结及血行转移因素分析 被引量:12

Factors of lymph node and blood metastasis in occult thyroid carcinoma
下载PDF
导出
摘要 目的 探讨隐匿性甲状腺癌淋巴结及血行转移特点,为手术治疗提供依据。方法 对64 例隐匿性甲状腺癌临床资料进行回顾性分析。结果 颈淋巴结转移39 例,转移率60.9 % ;血行转移3 例,转移率4.6 % 。转移与病理类型及肿瘤局部浸润程度有关,与原发灶大小无关。结论 隐匿性甲状腺癌转移特点与其同型的显性甲状腺癌相一致,治疗应遵循同类型显性癌的治疗原则。 Objective To investigate the transfering characteristics of lymph node and blood metastasis in occult thyroid carcinoma(OTC) for the surgical management. Methods Retrospective analysis on the clinical data of 64 cases of OTC. Results Thirty nine patients(60.9%) with cervical lymphatic metastasis and 3 patients(4.6%) with blood metastasis respectively. Metastasis was found to be related to the pathological type and invasive extension of the tumor, exclusive to the size of primary lesion. Conclusions The biological characteristic of OTC accords with that of the same type as thyroid carcinoma, and the relevant treatment also follows on the principals of the same type of thyroid carcinoma.
出处 《中国普通外科杂志》 CAS CSCD 1999年第5期351-353,共3页 China Journal of General Surgery
关键词 甲状腺肿瘤 肿瘤转移 淋巴结转移瘤 血行转移 THYROID NEOPLASMS/PP ADENOCARCINOMA/PP NEOPLASM METASTASIS FLLOW UP STUDIES
  • 相关文献

同被引文献59

  • 1宋明,陈福进,伍国号,杨安奎,陈文宽,欧阳电.甲状腺癌不规范手术后再手术相关问题的探讨[J].中华耳鼻咽喉科杂志,2004,39(8):451-455. 被引量:35
  • 2吴毅,王俊德.匿性甲状腺癌[J].中华外科杂志,1993,31(10):609-611. 被引量:18
  • 3孙敏,魏守杰,衣龙海,梁恩虎,徐忠法,左文述,张鑫,顾禾,石学涛,马恒.甲状腺癌误诊原因探讨(附59例分析)[J].中国肿瘤临床,1989,16(5):296-297. 被引量:3
  • 4李荫山.隐匿型甲状腺癌的诊治[J].中国实用外科杂志,1995,15(2):72-73. 被引量:14
  • 5余树观 叶真 等.原发灶不明的颈部转移癌200例临床研究[J].癌症,1988,7(4):288-288.
  • 6张众.甲状腺癌病理类型与治疗的关系[J].实用外科杂志,1986,6(5):231-231.
  • 7Lang BH, Lo CY, Chan WF, et al. Staging systems for follicular thyroid carcinoma : application to 171 consecutive patients treated in a tertiary referral centre [ J ]. Endocr Relat Cancer, 2007, 14(1) :29 -42.
  • 8Powell JG, Wang XY, Allard BL, et al. The PAX 8 / PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibition [ J ]. Oncogene, 2004, 23 (20) : 3634 - 3641.
  • 9Mclver B, Grebe SKG, Eberhardt NL. The PAX8/PPARγ fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma [ J ]. Curr Drug Targets Immune Endocr Metabol Disord, 2004, 4(3): 221 -234.
  • 10Foukakis T, AU AYM, Wallin G, et al. The Ras effector NORE 1 A is suppressed in follicular thyroid carcinomas with a PAX8-PPARγ, fusion [ J ] . J Clin Endocrin Metab, 2006 , 91 (3) :1143 -1149.

引证文献12

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部